Compare Kraft Heinz Co (KHC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Sana Biotechnology Inc — how do they compare? Kraft Heinz Co trades at $24.46 (market cap $29.23B), while Sana Biotechnology Inc trades at $3.73 (market cap $1.13B). The key difference: Kraft Heinz Co is far larger — about 25.9× Sana Biotechnology Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KHC | SANA | |
|---|---|---|
Market Cap | $29.23B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $28.06 | $5.92 |
52-Week Low | $21.21 | $2.68 |
Enterprise Value | $45.55B | $1.05B |
Dividend Yield | 6.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $24.36, down 2.29% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates, but net income margin is negative at -13.64%. The company maintains a $0.40 quarterly dividend, while analyst consensus is mostly Hold. Cash flow from operations improved to $4.46B in 2025, though revenue declined to $24.94B.
Outlook remains cautious due to profit declines and competitive pressures, offset by a low P/E of 13.04 and strategic investments. Key risks include earnings sustainability and high debt. The stock presents value potential but requires monitoring of turnaround execution under CEO Cahillane's strategy.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
